Japan Society to Select Facilities to Use Luxturna; 10 Sites for Genetic Testing, 2 or 3 for Treatment

The Japanese Retina and Vitreous Society aims to select facilities to handle Novartis’ gene therapy Luxturna (voretigene neparvovec) by the end of the year, looking to designate around 10 sites for genetic testing and two or three for treatments throughout...read more